As these data collectively suggest that GPS2 promotes the progression of fatty liver disease via antagonizing PPARα, the selective therapeutic modulation of GPS2–PPARα interactions could be of interest for future disease interventions. The gene discussed is GPS2; the disease is fatty liver disease.